ABPI outlines new Phase I guidelines

Responding to the scandal that erupted in the UK following a disastrous early-stage trial that sent six volunteers to the hospital, the Association of the British Pharmaceutical Industry has published new guidelines for Phase I studies which are designed to help avoid a repeat performance.

"Safety of volunteers for Phase 1 clinical trials is paramount, and this is at the heart of the revised guidelines," said Dr Richard Barker, ABPI Director General. "While the events surrounding the TGN1412 trial were unprecedented, we nevertheless have to do everything to ensure that they never occur again. As a result, conclusions and recommendations made in Sir Gordon Duff's report have been incorporated into the revised guidance."

- check out the release on the new guidelines

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.